Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CAMK2D
REST API REST API
Homo sapiens
CAMK2D is differentially expressed in 237 experiments: 99 organism parts: bone marrow, amygdala, ... (97 more);, 93 disease states: normal, breast carcinoma, ... (91 more);, 79 cell types 345 cell lines 28 compound treatments and 52 other conditions.
Synonyms CAMKD
Orthologs ENSCING00000002022 (Ciona intestinalis)   KCC2D_RAT (Rattus norvegicus)   CMK2 (Saccharomyces cerevisiae)   camk2d2 (Danio rerio)   CMK1 (Saccharomyces cerevisiae)   KCC2D_BOVIN (Bos taurus)   CAMK2D (Gallus gallus)   Camk2d (Mus musculus)   CaMKII (Drosophila melanogaster)   camk2d (Xenopus laevis)   CAMK2D (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, cytokine-mediated signaling pathway, cytoplasm, regulation of heart contraction, protein tyrosine kinase activity, calmodulin-dependent protein kinase activity, sarcoplasmic reticulum membrane, calmodulin binding, ATP binding, cardiac muscle contraction, synaptic transmission, neuromuscular junction, G1/S transition of mitotic cell cycle, nucleus, nucleotide binding, regulation of cell growth, protein serine/threonine kinase activity, nucleoplasm, calcium ion transport, calcium- and calmodulin-dependent protein kinase complex, protein kinase activity, T-tubule, positive regulation of cardiac muscle hypertrophy, protein autophosphorylation, protein phosphorylation, regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion, regulation of ryanodine-sensitive calcium-release channel activity, interferon-gamma-mediated signaling pathway, endocytic vesicle membrane, regulation of cellular localization
InterPro Term Ca/CaM-dep_prot_kinase-assoc, Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q92991, D6R938, Q13557, E9PBG7, E9PF82
Search EB-eye ENSG00000145349
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-GEOD-6919, E-TABM-130, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-4219, E-GEOD-3202, E-GEOD-6013, ... (27 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-GEOD-15460, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
K562
2
E-MTAB-37, E-GEOD-24147
339 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (34 experiments)

Factor Value U/D Experiments
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
not specified
2
E-GEOD-18811, E-GEOD-11755
stromal cell
2
E-GEOD-1460, E-GEOD-3998
memory B cell
1
2
E-GEOD-17186, E-TABM-702, E-MEXP-2360
hematopoietic stem cell
1
E-MEXP-1403
fetal RPE
1
E-GEOD-18811
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-MEXP-1121, ... (45 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
2
E-GEOD-4290, E-MTAB-37
juvenile idiopathic arthritis subtype oligoarthritis
1
E-GEOD-13501
anaplastic large cell lymphoma
1
E-GEOD-6338
Emery-Dreifuss muscular dystrophy
1
E-GEOD-3307
87 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (18 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
3
4
E-MEXP-1958, E-GEOD-5741, E-GEOD-7400, E-GEOD-20719, E-TABM-868, ... (7 experiments)
SDF
1
E-GEOD-7307
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
filtered air
1
E-TABM-127
TTA
1
E-MEXP-2590
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19246, E-GEOD-21374, E-GEOD-21589, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-GEOD-13073, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-19018, ... (8 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (28 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-22541, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.348 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM